OBJECTIVE: Several factors that are related to ovulation are relevant to ovarian cancer risk, but it is unclear whether they can be included in a single definition of years of ovulation. STUDY DESIGN: We considered data from 2 case-control studies of ovarian cancer that were conducted in Italy and included 1822 histologically confirmed cases and 4631 control subjects who were hospitalized for acute conditions. RESULTS: As compared with the lowest quartile, the odds ratios of ovarian cancer were 1.60 (95% CI, 1.31-1.95), 1.65 (95% CI, 1.34-2.03), and 1.81 (95% CI, 1.47-2.23) for increasing quartiles of lifetime ovulatory cycles. For 1 year of ovulation avoided, the continuous odds ratios were 0.975 (95% CI, 0.965-0.985) for total ovulatory cycles, 0.91 (95% CI, 0.87-0.95) for parity-related anovulations, 0.90 (95% CI, 0.76-1.06) for abortions, 0.92 (95% CI, 0.87-0.97) for oral contraceptive use, 0.99 (95% CI, 0.96-1.03) for age at menarche, and 0.97 (95% CI, 0.95-0.98) for age at menopause. Women who reported high numbers of ovulatory cycles and family history of ovarian/breast cancers had an odds ratio of 3.27 (95% CI, 2.44-4.36). CONCLUSION: This study found that pregnancy and oral contraceptive use had a stronger protective effect on ovarian cancer than other anovulatory factors.
OBJECTIVE: Several factors that are related to ovulation are relevant to ovarian cancer risk, but it is unclear whether they can be included in a single definition of years of ovulation. STUDY DESIGN: We considered data from 2 case-control studies of ovarian cancer that were conducted in Italy and included 1822 histologically confirmed cases and 4631 control subjects who were hospitalized for acute conditions. RESULTS: As compared with the lowest quartile, the odds ratios of ovarian cancer were 1.60 (95% CI, 1.31-1.95), 1.65 (95% CI, 1.34-2.03), and 1.81 (95% CI, 1.47-2.23) for increasing quartiles of lifetime ovulatory cycles. For 1 year of ovulation avoided, the continuous odds ratios were 0.975 (95% CI, 0.965-0.985) for total ovulatory cycles, 0.91 (95% CI, 0.87-0.95) for parity-related anovulations, 0.90 (95% CI, 0.76-1.06) for abortions, 0.92 (95% CI, 0.87-0.97) for oral contraceptive use, 0.99 (95% CI, 0.96-1.03) for age at menarche, and 0.97 (95% CI, 0.95-0.98) for age at menopause. Women who reported high numbers of ovulatory cycles and family history of ovarian/breast cancers had an odds ratio of 3.27 (95% CI, 2.44-4.36). CONCLUSION: This study found that pregnancy and oral contraceptive use had a stronger protective effect on ovarian cancer than other anovulatory factors.
Authors: Holly R Harris; Ana Babic; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; Catherine M Phelan; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Kathryn L Terry Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-15 Impact factor: 4.254
Authors: Tianyi Huang; Amy L Shafrir; A Heather Eliassen; Kathryn M Rexrode; Shelley S Tworoger Journal: Am J Epidemiol Date: 2020-07-01 Impact factor: 4.897
Authors: Sarah R Irvin; Elisabete Weiderpass; Frank Z Stanczyk; Louise A Brinton; Britton Trabert; Hilde Langseth; Nicolas Wentzensen Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-01-13 Impact factor: 4.254
Authors: Mollie E Barnard; Elizabeth M Poole; Gary C Curhan; A Heather Eliassen; Bernard A Rosner; Kathryn L Terry; Shelley S Tworoger Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777
Authors: Hannah P Yang; Kelsey R Murphy; Ruth M Pfeiffer; Neena George; Montserrat Garcia-Closas; Jolanta Lissowska; Louise A Brinton; Nicolas Wentzensen Journal: Am J Epidemiol Date: 2016-04-15 Impact factor: 4.897
Authors: Kristina A Williams; S Intidhar Labidi-Galy; Kathryn L Terry; Allison F Vitonis; William R Welch; Annekathryn Goodman; Daniel W Cramer Journal: Gynecol Oncol Date: 2014-01-23 Impact factor: 5.482
Authors: Elizabeth M Poole; I-Min Lee; Paul M Ridker; Julie E Buring; Susan E Hankinson; Shelley S Tworoger Journal: Am J Epidemiol Date: 2013-08-21 Impact factor: 4.897
Authors: Britton Trabert; Shelley S Tworoger; Katie M O'Brien; Mary K Townsend; Renée T Fortner; Edwin S Iversen; Patricia Hartge; Emily White; Pilar Amiano; Alan A Arslan; Leslie Bernstein; Louise A Brinton; Julie E Buring; Laure Dossus; Gary E Fraser; Mia M Gaudet; Graham G Giles; Inger T Gram; Holly R Harris; Judith Hoffman Bolton; Annika Idahl; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Marina Kvaskoff; James V Lacey; I-Min Lee; Roger L Milne; N Charlotte Onland-Moret; Kim Overvad; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Elio Riboli; Kim Robien; Thomas E Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Veronica W Setiawan; Anthony J Swerdlow; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Kala Visvanathan; Lynne R Wilkens; Alicja Wolk; Anne Zeleniuch-Jacquotte; Nicolas Wentzensen Journal: Cancer Res Date: 2020-01-13 Impact factor: 12.701